

Study Number: C12010-01
Test Type: TOX
Route: Oral Gavage
Species/Strain: Rat/Harlan Sprague Dawley

PA41: Clinical Chemistry Summary
Test Compound: Drometrizole
CAS Number: 2440-22-4

Date Report Requested: 05/19/2021
Time Report Requested: 07:38:03
Lab: Battelle

Study Number: C12010-01
Study Sex: Male
PWG Approval Date: See web page for date of PWG Approval
Version: v1.2.0

Study Number: C12010-01

Test Type: TOX

Route: Oral Gavage

Species/Strain: Rat/Harlan Sprague Dawley

PA41: Clinical Chemistry Summary

Test Compound: Drometrizole

CAS Number: 2440-22-4

Date Report Requested: 05/19/2021

Time Report Requested: 07:38:03

Lab: Battelle

Male						
	Phase Day	Treatment Groups (mg/kg)				
		0	30	100	300	1000
Urea Nitrogen (mg/dL)	SD 14	15.0 ± 0.8 (5)	17.2 ± 0.6 (5)	17.4 ± 0.4 (5)	15.8 ± 0.4 (5)	17.8 ± 1.3 (5)
Percent of Control			114.7	116.0	105.3	118.7
Creatinine (mg/dL)	SD 14	0.38 ± 0.02 (5)	0.36 ± 0.02 (5)	0.40 ± 0.00 (5)	0.38 ± 0.02 (5)	0.36 ± 0.02 (5)
Percent of Control			94.7	105.3	100.0	94.7
Glucose (mg/dL)	SD 14	174.4 ± 8.8 (5)	183.6 ± 9.2 (5)	205.8 ± 16.2 (5)	159.0 ± 9.6 (5)	167.8 ± 18.5 (5)
Percent of Control			105.3	118.0	91.2	96.2
Total Protein (g/dL)	SD 14	6.64 ± 0.08 (5)	6.54 ± 0.06 (5)	6.68 ± 0.09 (5)	6.96 ± 0.10 (5)	6.62 ± 0.09 (5)
Percent of Control			98.5	100.6	104.8	99.7
Globulin (g/dL)	SD 14	2.28 ± 0.06 (5)	2.18 ± 0.05 (5)	2.30 ± 0.07 (5)	2.44 ± 0.04 (5)	2.24 ± 0.07 (5)
Percent of Control			95.6	100.9	107.0	98.2
A/G Ratio	SD 14	1.92 ± 0.04 (5)	2.00 ± 0.06 (5)	1.91 ± 0.05 (5)	1.85 ± 0.04 (5)	1.96 ± 0.06 (5)
Percent of Control			104.6	99.7	96.7	102.4
Albumin (g/dL)	SD 14	4.36 ± 0.04 (5)	4.36 ± 0.05 (5)	4.38 ± 0.02 (5)	4.52 ± 0.08 (5)	4.38 ± 0.05 (5)
Percent of Control			100.0	100.5	103.7	100.5
Cholesterol (mg/dL)	SD 14	117.8 ± 10.2 (5) **	119.0 ± 2.7 (5)	136.8 ± 6.4 (5)	134.8 ± 5.7 (5)	149.4 ± 9.6 (5) *
Percent of Control			101.0	116.1	114.4	126.8
Triglyceride (mg/dL)	SD 14	97.0 ± 9.7 (5)	107.8 ± 4.0 (5)	133.6 ± 24.6 (5)	113.8 ± 14.6 (5)	113.4 ± 11.2 (5)
Percent of Control			111.1	137.7	117.3	116.9
Alanine Aminotransferase (IU/L)	SD 14	54.4 ± 2.7 (5)	51.0 ± 3.6 (5)	58.4 ± 3.5 (5)	54.0 ± 2.2 (5)	73.6 ± 18.3 (5)
Percent of Control			93.8	107.4	99.3	135.3
Alkaline Phosphatase (IU/L)	SD 14	206.0 ± 12.1 (5)	196.6 ± 8.5 (5)	209.4 ± 7.8 (5)	205.4 ± 8.7 (5)	194.0 ± 9.7 (5)
Percent of Control			95.4	101.7	99.7	94.2

Study Number: C12010-01

Test Type: TOX

Route: Oral Gavage

Species/Strain: Rat/Harlan Sprague Dawley

PA41: Clinical Chemistry Summary

Test Compound: Drometrizole

CAS Number: 2440-22-4

Date Report Requested: 05/19/2021

Time Report Requested: 07:38:03

Lab: Battelle

Male

		Treatment Groups (mg/kg)									
Phase Day		0		30		100		300		1000	
Creatine Kinase (IU/L)	SD 14	146.2	± 28.8 (5)	152.8	± 29.6 (5)	144.0	± 11.2 (5)	186.8	± 44.9 (5)	230.6	± 94.0 (5)
Percent of Control				104.5		98.5		127.8		157.7	
Sorbitol Dehydrogenase (IU/L)	SD 14	9.0	± 0.9 (5) *	7.0	± 1.1 (5)	8.8	± 0.6 (5)	10.2	± 0.6 (5)	14.0	± 2.8 (5)
Percent of Control				78.2		98.2		113.4		156.3	
Bile salt/acids (umol/L)	SD 14	16.2	± 4.4 (5)	16.6	± 3.9 (5)	28.4	± 2.3 (5)	23.8	± 5.6 (5)	27.8	± 9.1 (5)
Percent of Control				102.5		175.3		146.9		171.6	

Study Number: C12010-01

Test Type: TOX

Route: Oral Gavage

Species/Strain: Rat/Harlan Sprague Dawley

PA41: Clinical Chemistry Summary

Test Compound: Drometrizole

CAS Number: 2440-22-4

Date Report Requested: 05/19/2021

Time Report Requested: 07:38:03

Lab: Battelle

LEGEND

Values given as mean $\pm$ SEM (N) with Percent of Control calculated by (dosed group mean / control group mean) x 100

SD – Study Day

Statistical analysis were performed by Jonckheere (trend) and Shirley or Dunn (pairwise) tests.

Statistical significance for the control group indicates a significant trend test

Statistical significance for a treatment group indicates a significant pairwise test compared to the vehicle control group

* Statistically significant at $P \leq 0.05$

** Statistically significant at $P \leq 0.01$

**** END OF REPORT ****